SEC Enforcement Activity: Public Companies and Subsidiaries

Featured Experts

Featured Experts

James W. Hughes

Thomas Sowell Professor of Economics Emeritus,
Bates College

James Hughes has served as an expert witness in a variety of antitrust, regulatory, labor discrimination, and product misrepresentation matters in industries that span healthcare, life sciences, commodities, and services. His recent work has focused on class certification issues in the pharmaceutical industry.

Professor Hughes provided expert testimony In re Pharmaceutical Industry Average Wholesale Price Litigation and In re Skelaxin (Metaxalone) Antitrust Litigation, as well as in several relator cases. He has consulted in matters involving the prescription pharmaceuticals Cipro, Cardizem CD, Neurontin, Rezulin, Procardia XL, and Provigil.

Professor Hughes researches issues in law and economics, pharmaceuticals, healthcare, regulation, labor economics, and antitrust economics. He has studied how generic prescription drug laws may affect innovation rates in research pharmaceutical companies, and the impact of tobacco taxes on healthcare utilization.

At Bates College, Professor Hughes received awards for excellence in teaching. Previously, he was on the faculty at Amherst College and the State University of New York at Albany. His articles have appeared in numerous scholarly journals, including the American Economic Review, the International Review of Law and Economics, and the Journal of Law and Economics.

Featured Experts

Jonathan P. Jarow

CEO and Founder, FDA Solutions LLC;
Former Chief Medical Officer, Office of Device Evaluation (CRDH),
Former Senior Medical Advisor to the Center Director (CDER),
Food and Drug Administration (FDA)

Jonathan Jarow is an expert on the FDA’s regulation of innovative pharmaceutical products and medical devices. A board-certified physician, he is the founder and CEO of FDA Solutions LLC, a consulting firm serving FDA-regulated companies.

Prior to founding FDA Solutions, Dr. Jarow spent almost ten years at the FDA in various leadership roles. He has been a primary clinical reviewer of investigational new drugs (INDs), new drug applications (NDAs), Biologics License Applications (BLAs), and Premarket Approvals (PMAs). In addition, he has led multidisciplinary professional staff in the development of high-priority FDA policies and programs. Dr. Jarow’s policy and implementation experience includes expedited drug development and approval pathways, drug recalls, rare diseases, human factor studies, software as a medical device, drug pricing, product labeling, and advertising and promotion.

Before joining the FDA, Dr. Jarow was Professor of Urology, Pathology, Radiology, and Biochemistry & Molecular Biology at Johns Hopkins University School of Medicine. He also served as clinical investigator for industry-sponsored clinical trials. Dr. Jarow’s clinical practice at Johns Hopkins focused on traditional and robotic surgery. Previously, he was associate professor of urology and obstetrics/gynecology at Wake Forest University’s Bowman Gray School of Medicine.

Dr. Jarow is the author of more than one hundred peer-reviewed publications. His research has appeared in the Journal of the American Medical Association (JAMA), the New England Journal of Medicine, and Nature Reviews Drug Discovery, among others.

Dr. Jarow has served as an expert witness and has extensive deposition and trial experience, including in federal, state, and international arbitration courts.

Featured Experts

Alice Chen

Associate Professor,
Sol Price School of Public Policy;
Senior Fellow,
Leonard D. Schaeffer Center for Health Policy and Economics,
University of Southern California

Alice Chen specializes in health economics and labor economics. Professor Chen has expertise in a range of issues involving healthcare and pharmaceutical firms, including pharmaceutical competition and innovation, healthcare labor markets, and provider payment models.

Professor Chen has served as a consulting damages expert on life sciences matters, estimating the impact of allegedly false pharmaceutical marketing on prescription drug sales. In healthcare matters, she has offered written and deposition testimony on health insurance plan design in relation to class certification. She has testified at trial on statistical analyses of clinical trial data and regulatory drug approval. Professor Chen has also provided healthcare consulting services to pharmaceutical companies, including analyses of drug clinical trial data.

Professor Chen’s research has focused on improving the efficiency of healthcare markets, biologics and biosimilars innovation and competition, and the drivers and impacts of healthcare provider behavior. Her recent research analyzes the impact of Medicare policies on provider treatment decisions and healthcare outcomes and potential impacts of the Inflation Reduction Act on drug competition, pricing, and innovation. Professor Chen has presented her work before regulators at the Federal Trade Commission and the Congressional Budget Office.

Professor Chen has published articles in leading economics, health policy, and medical journals, including the American Economic Journal: Economic PolicyHealth AffairsJAMA Internal Medicine, and the Journal of Health Economics. Her research has also been cited in major media outlets, including BloombergCBS NewsForbes, the New York Times, and the Washington Post.

At USC Price, Professor Chen teaches undergraduate- and graduate-level courses in health economics and health finance. The USC Health Administration Graduate Program has recognized her as Outstanding Faculty of the Year.

Featured Experts

Donna L. Hoffman

Professor of Marketing,
Louis Rosenfeld Distinguished Scholar,
GW School of Business,
The George Washington University

Donna Hoffman is a world-renowned expert in online consumer experience and behavior, including how consumers react to information and disclosures in digital and online settings. Professor Hoffman is also a leading scholar on the impact of artificial intelligence (AI) and the Internet of Things (IoT) on consumer perceptions and behavior. She has extensive experience with survey methods and content analysis.

Professor Hoffman has testified in multiple matters, including in two federal trials. Her testimony in these matters included evaluating and opining on issues relating to online consumer behavior, digital marketing, and the role of internet search in the purchase decision process. Professor Hoffman has also applied her expertise to evaluate allegations of dark patterns in online user interfaces and their influence on user perceptions, decisions, and behavior. Some of her work in these contexts has involved data privacy issues.

Professor Hoffman cofounded and codirects the Center for the Connected Consumer, an academic research center dedicated to understanding consumer experiences with AI and smart devices that are connected to the internet.

Professor Hoffman’s research has appeared in top academic and managerial publications, such as Marketing ScienceManagement Science, the Journal of Marketing Research, the Journal of Marketing, the Journal of Consumer Research, and the Journal of Consumer Psychology. She currently serves on the editorial boards of leading academic publications in the marketing discipline, as well as serving as an associate editor at the Journal of Marketing. She coedited the book Beyond the Basics: Research-Based Rules for Internet Retailing Advantage and has coauthored numerous book chapters focused on consumer behavior in online environments.

One of the most highly cited scholars in the marketing field, Professor Hoffman has received many prestigious research awards. These include the Society for Consumer Psychology Fellow Award; the Robert B. Clarke Educator of the Year Award from Marketing EDGE (formerly the DMEF); the Sheth Foundation/Journal of Marketing Award for long-term contributions to the marketing discipline; and the William O’Dell/Journal of Marketing Research Award for long-term research impact.

Professor Hoffman has consulted to major corporations on electronic commerce and digital marketing strategy, including FedEx.com, Intel, Lands’ End/Sears, Microsoft, Procter & Gamble, and Walmart.com. She also served as a member of the Procter & Gamble Digital Advisory Board.

About Us

For thirty-five years, Cornerstone Research staff have provided economic and financial analysis in all phases of commercial litigation and regulatory proceedings.

Diversity, Equity, and Inclusion

The varied backgrounds, experiences, and perspectives of our people strengthen our firm and enrich the support we provide to our clients and experts.

Pro Bono

Cornerstone Research is committed to making a positive impact in the communities where we live and work.

Insights

12 December 2024

Women’s Antitrust Forum 2024: Luminary Event

Joanna Tsai of Cornerstone Research will lead a Q&A session at this Washington, DC gathering of leading women antitrust practitioners.

3 December 2024

Cornerstone Research Again Earns Top 10 Spot in Vault’s Rankings of Best Consulting Internships

Cornerstone Research’s summer analyst program offers top training, data analytics experience, a supportive culture, and outstanding benefits.

3 December 2024

Corporate Disputes 2024 – 4th Annual Forum

Ronnie Barnes of Cornerstone Research will join a panel to discuss the role of experts in corporate disputes at this conference in London.

25 November 2024

Informa Advanced EU Competition Law 2024

Cornerstone Research professionals will discuss merger control issues in Europe at this annual conference in Brussels.

25 November 2024

Our Curious Amalgam: Are Airline Mergers Taking Off?

Gautam Gowrisankaran of Columbia University discussed economic analyses in specific airline transactions in this podcast hosted by the ABA.

22 November 2024

Dublin International Arbitration Day 2024

Ronnie Barnes of Cornerstone Research will join a rapid-fire question-and-answer session at this annual conference in Ireland.

21 November 2024

SEC Enforcement Actions Against Public Companies and Subsidiaries Drop by 12% in FY 2024; Actions Still Up Nearly 5% Compared to Historical Average

Off-channel communications continues as an enforcement priority, driving Broker Dealer allegations to 29% of FY 2024 actions.

20 November 2024

Assessing Settlement Outcomes and Damages in Securities Class Actions

Filipe Lacerda of Cornerstone Research will discuss trends in securities litigation in the U.S. at a Quinn Emanuel Urquhart & Sullivan event.

20 November 2024

Expert Forum: Frontline Perspectives on Recent Developments in Competition Litigation, AI and Mergers

This Cornerstone Research conference in London addresses issues related to competition class actions, AI regulation, and remedies in mergers.

19 November 2024

In the Matter of WillScot and McGrath

The parties abandoned the merger.

How can we help you?

For more information or assistance with a specific matter, please contact us.